A novel RyR2 mutation (c.6251T>C, p.Met2084Thr) was identified in a 28-year-old male presenting with out-of-hospital cardiac arrest due to CPVT, highlighting the importance of genetic testing in inherited arrhythmias.
Novel CPVT case extends phenotypic spectrum; hypothesis-generating and requires prospective validation before clinical adoption.
Inherited arrhythmia syndromes remain an important and increasingly recognized cause of ventricular tachycar dia (VT) and sudden cardiac death. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal, heritable cardiac arrhythmia that occurs in response to physical or emotional stress, it often manifests as exercise-induced ventricular arrhythmias, syncope, or sudden death. If untreated, catecholaminergic polymorphic ventricular tachycardia is a highly lethal condition: About 80% of affected individuals experience recurrent syncope, and 30% experience cardiac arrest. CPVT is caused by mutations in genes encoding proteins involved in calcium handling in cardiomyocytes, such as the cardiac ryanodine receptor (RyR2). RyR2 mutations impair the regulation of calcium release from the sarcoplasmic reticulum, leading to delayed afterdepolarizations and triggered arrhythmias. Here, we report a case of CPVT in a patient with RyR2 gene mutation, causing sudden cardiac arrest.
No takes yet. Share an insight, caveat, or question.
A 2023 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: